The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Abacavir/Lamivudine Mylan 600 mg/300 mg film-coated tablets

600mg/300 milligram(s) Film-coated tablet

McDermott Laboratories Ltd., T/A Gerard LaboratoriesPA0577/193/001

Main Information

Trade NameAbacavir/Lamivudine Mylan 600 mg/300 mg film-coated tablets
Active SubstancesAbacavir
Lamivudine
Strength600mg/300 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderMcDermott Laboratories Ltd., T/A Gerard Laboratories
Licence NumberPA0577/193/001

Group Information

ATC CodeJ05AR Antivirals for treatment of HIV infections, combinations
J05AR02 lamivudine and abacavir

Status

Authorised/WithdrawnAuthorised
Licence Issued07/10/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back